Korean J healthc assoc Infect Control Prev.  2023 Dec;28(2):185-191. 10.14192/kjicp.2023.28.2.185.

The Value and Clinical Application of Carbapenem-resistant Enterobacterales Surveillance Culture

• Lee KH

• KMID: 2549945
• DOI: http://doi.org/10.14192/kjicp.2023.28.2.185

Abstract

Carbapenem-resistant Enterobacterales (CRE) is an urgent and increasing threat worldwide. It can be spread by contact transmission, causing intra-hospital outbreaks; therefore, screening for CRE using surveillance culture is critical. It is essential to identify risk factors for CRE transmission, such as history of antibiotic use, previous bacterial culture results, and invasive catheterization. Subsequently, surveillance cultures should be selectively implemented while maintaining close organizational communication with the surrounding medical facilities. This protocol can be clinically applied at admission for groups at high risk of CRE colonization, then biweekly in special situations such as intensive care unit admission or contact with a patient colonized with carbapenemase-producing Enterobacterales (CPE). In addition, surveillance culture methods should be selected in a mutually complementary manner according to each institution and laboratory environment. Ultimately, various surveillance culture protocols will be necessary as suitable for individual medical infrastructures, patients, and indications for testing intervals.

Keyword

Carbapenem-resistant; Enterobacterales; Surveillance; Screening; Carbapenemase

Figure

• 

  Fig. 1 Total number of CRE isolates for 6 years in South Korea (2017- 2022). Abbreviation: CRE, carbapenem resistant Enterobacterales.

• 

  Fig. 2 Flow chart of CRE screening and isolation. Abbreviation: CRE, carbapenem resistant Enterobacterales.

Reference

1. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. 2018; Carbapenemase-producing organisms: a global scourge. Clin Infect Dis. 66:1290–7. DOI: 10.1093/cid/cix893. PMID: 29165604. PMCID: PMC5884739.

2. Logan LK, Weinstein RA. 2017; The epidemiology of carbapenem- resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 215(suppl_1):S28–36. DOI: 10.1093/infdis/jiw282. PMID: 28375512. PMCID: PMC5853342.

3. Soontaros S, Leelakanok N. 2019; Association between carbapenem-resistant Enterobacteriaceae and death: a systematic review and meta-analysis. Am J Infect Control. 47:1200–12. DOI: 10.1016/j.ajic.2019.03.020. PMID: 31072673.

4. Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. 2017; Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 23:48.e9–16. DOI: 10.1016/j.cmi.2016.09.003. PMID: 27642178. PMCID: PMC5547745.

5. Schwartz-Neiderman A, Braun T, Fallach N, Schwartz D, Carmeli Y, Schechner V. 2016; Risk factors for carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) acquisition among contacts of newly diagnosed CP-CRE patients. Infect Control Hosp Epidemiol. 37:1219–25. DOI: 10.1017/ice.2016.153. PMID: 27452597.

6. Tischendorf J, de Avila RA, Safdar N. 2016; Risk of infection following colonization with carbapenem-resistant Enterobactericeae: a systematic review. Am J Infect Control. 44:539–43. DOI: 10.1016/j.ajic.2015.12.005. PMID: 26899297. PMCID: PMC5262497.

7. Kim MK, Joo S, Shin E, Kim J, Yoo J. 2023; Antimicrobial resistance and molecular characteristics of carbapenem-resistant Enterobacteriaceae isolated in the Republic of Korea, 2021. Public Health Wkly Rep. 16:541–59.

8. Suay-García B, Pérez-Gracia MT. 2019; Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections. Antibiotics (Basel). 8:122. DOI: 10.3390/antibiotics8030122. PMID: 31430964. PMCID: PMC6784177.

9. Korea Disease Control. 2022. Healthcare associated Infectious diseases management guideline, 2022. Korea Disease Control and Prevention Agency;Cheongju: p. 46–116.

10. Centers for Disease Control. 2015. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). Centers for Disease Control and Prevention;Atlanta: p. 3–18.

11. Barnes SL, Morgan DJ, Harris AD, Carling PC, Thom KA. 2014; Preventing the transmission of multidrug-resistant organisms: modeling the relative importance of hand hygiene and environmental cleaning interventions. Infect Control Hosp Epidemiol. 35:1156–62. DOI: 10.1086/677632. PMID: 25111924. PMCID: PMC4204209.

12. Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, et al. 2017; Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 64:257–64. DOI: 10.1093/cid/ciw741. PMID: 28013264. PMCID: PMC5241781.

13. Ben-David D, Maor Y, Keller N, Regev-Yochay G, Tal I, Shachar D, et al. 2010; Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol. 31:620–6. DOI: 10.1086/652528. PMID: 20370465.

14. Lutgring JD, Limbago BM. 2016; The problem of carbapenemase-producing-carbapenem-resistant-Enterobacteriaceae detection. J Clin Microbiol. 54:529–34. DOI: 10.1128/JCM.02771-15. PMID: 26739152. PMCID: PMC4767976.

15. Li HH, He ZJ, Xie LM, Zhang JS, Xie TA, Fan SJ, et al. 2021; Evaluation of Xpert Carba-R assay for the detection of carbapenemase genes in gram-negative bacteria. Biomed Res Int. 2021:6614812. DOI: 10.1155/2021/6614812. PMID: 33928150. PMCID: PMC8049809.

16. Richter SS, Marchaim D. 2017; Screening for carbapenem-resistant Enterobacteriaceae: who, when, and how? Virulence. 8:417–26. DOI: 10.1080/21505594.2016.1255381. PMID: 27813699. PMCID: PMC5477693.

17. Adler A, Navon-Venezia S, Moran-Gilad J, Marcos E, Schwartz D, Carmeli Y. 2011; Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J Clin Microbiol. 49:2239–42. DOI: 10.1128/JCM.02566-10. PMID: 21471338. PMCID: PMC3122751.

18. Weinstein JW, Tallapragada S, Farrel P, Dembry LM. 1996; Comparison of rectal and perirectal swabs for detection of colonization with vancomycin-resistant enterococci. J Clin Microbiol. 34:210–2. DOI: 10.1128/jcm.34.1.210-212.1996. PMID: 8748308. PMCID: PMC228765.

19. Gomides MDA, Fontes AMS, Silveira AOSM, Matoso DC, Ferreira AL, Sadoyama G. 2022; The importance of active surveillance of carbapenem-resistant Enterobacterales (CRE) in colonization rates in critically ill patients. PLoS One. 17:e0262554. DOI: 10.1371/journal.pone.0262554. PMID: 35051212. PMCID: PMC8775193.

20. Calderaro A, Buttrini M, Martinelli M, Montecchini S, Covan S, Ruggeri A, et al. 2021; Active surveillance for carbapenemase-producing Klebsiella pneumoniae and correlation with infection in subjects attending an Italian tertiary-care hospital: a 7-year retrospective study. BMJ Open. 11:e042290. DOI: 10.1136/bmjopen-2020-042290. PMID: 33875440. PMCID: PMC8057555.

21. Wangchinda W, Thamlikitkul V, Watcharasuwanseree S, Tangkoskul T. 2022; Active surveillance for carbapenem-resistant Enterobacterales (CRE) colonization and clinical course of CRE colonization among hospitalized patients at a university hospital in Thailand. Antibiotics (Basel). 11:1401. DOI: 10.3390/antibiotics11101401. PMID: 36290059. PMCID: PMC9598097.

22. Kang JS, Yi J, Ko MK, Lee SO, Lee JE, Kim KH. 2019; Prevalence and risk factors of carbapenem-resistant Enterobacteriaceae acquisition in an emergency intensive care unit in a tertiary hospital in Korea: a case-control study. J Korean Med Sci. 34:e140. DOI: 10.3346/jkms.2019.34.e140. PMID: 31074254. PMCID: PMC6509365.

23. Kim YA, Lee SJ, Park YS, Lee YJ, Yeon JH, Seo YH, et al. 2020; Risk factors for carbapenemase-producing Enterobacterales infection or colonization in a Korean intensive care unit: a case-control study. Antibiotics (Basel). 9:680. DOI: 10.3390/antibiotics9100680. PMID: 33049912. PMCID: PMC7600752.

24. Lee KH, Kim D, Hong JS, Park SY, Cho NH, Kim MN, et al. 2023; Prevalence of carbapenemase producing Enterobacterales colonization and risk factor of clinical infection. J Infect Public Health. 16:1860–9. DOI: 10.1016/j.jiph.2023.09.010. PMID: 37837922.

25. Freire MP, de Oliveira Garcia D, Lima SG, Pea CRD, Reusing Junior JO, Spadão F, et al. 2022; Performance of two methods of carbapenem-resistant Enterobacterales surveillance on a kidney transplant ward: selective culture of and real-time PCR directly from rectal swabs. Infection. 50:1525–33. DOI: 10.1007/s15010-022-01839-2. PMID: 35534755.

26. Chen X, Wen X, Jiang Z, Yan Q. 2023; Prevalence and factors associated with carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies patients with CRE intestinal colonization. Ann Clin Microbiol Antimicrob. 22:3. DOI: 10.1186/s12941-023-00554-6. PMID: 36627626. PMCID: PMC9832636.

27. Iacchini S, Sabbatucci M, Gagliotti C, Rossolini GM, Moro ML, Iannazzo S, et al. 2019; Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017. Euro Surveill. 24:1800159. DOI: 10.2807/1560-7917.ES.2019.24.5.1800159. PMID: 30722813. PMCID: PMC6386214.